Bioblast Pharma Reports First Quarter 2017 Financial Results
26 mai 2017 16h15 HE
|
Bioblast Pharma
TEL AVIV, Israel, May 26, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the first...
Bioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders’ Equity and Minimum Bid Requirements
17 avr. 2017 16h47 HE
|
Bioblast Pharma
TEL AVIV, Israel, April 17, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that in response to a written...
Bioblast Announces Termination of Securities Offering
06 avr. 2017 16h55 HE
|
Bioblast Pharma
TEL AVIV, Israel, April 06, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today the cancellation of its...
Bioblast Pharma Announces Termination of Securities Offering
06 avr. 2017 16h01 HE
|
Bioblast Pharma
TEL AVIV, Israel, April 06, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today the cancellation of its...
Bioblast Pharma Announces Receipt of Nasdaq Notification Regarding Stockholders’ Equity
10 mars 2017 16h05 HE
|
Bioblast Pharma
TEL AVIV, Israel, March 10, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written...
Bioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results
24 févr. 2017 08h00 HE
|
Bioblast Pharma
TEL AVIV, Israel, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
Bioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and Other Neurodegenerative Diseases
01 févr. 2017 16h01 HE
|
Bioblast Pharma
TEL AVIV, Israel, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqGM:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced new clinical and development...
Bioblast Pharma to Host Key Opinion Leader Lunch Focused on Orphan Neurological Diseases on February 2
26 janv. 2017 08h00 HE
|
Bioblast Pharma
TEL AVIV, Israel, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, will host a KOL lunch on the subject of...
Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3)
18 janv. 2017 08h00 HE
|
Bioblast Pharma
Patients Treated with Trehalose Remained Stable According to a Well-Established Clinical Evaluation Scale A Recent Natural History Study in The Lancet Neurology in Patients with SCA3 Noted a Steady...
Bioblast Pharma Reports Third Quarter 2016 Financial Results
29 nov. 2016 08h00 HE
|
Bioblast Pharma
TEL AVIV, Israel, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...